VYNE PE Ratio & Valuation,Is VYNE Overvalued

VYNE Relative Valuation

VYNE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VYNE is overvalued; if below, it's undervalued.

Historical Valuation

Vyne Therapeutics Inc (VYNE) is now in the Fair zone, suggesting that its current forward PS ratio of 24.91 is considered Fairly compared with the five-year average of -1.82. The fair price of Vyne Therapeutics Inc (VYNE) is between 0.21 to 1.96 according to relative valuation methord.

Relative Value

Fair Zone

0.21-1.96

Current Price：0.58

Fair

-0.75

0.27

EV/EBITDA

Vyne Therapeutics Inc. (VYNE) has a current EV/EBITDA of 0.27. The 5-year average EV/EBITDA is 0.15. The thresholds are as follows: Strongly Undervalued below -2.32, Undervalued between -2.32 and -1.09, Fairly Valued between 1.38 and -1.09, Overvalued between 1.38 and 2.62, and Strongly Overvalued above 2.62. The current Forward EV/EBITDA of 0.27 falls within the Historic Trend Line -Fairly Valued range.

0.41

EV/EBIT

Vyne Therapeutics Inc. (VYNE) has a current EV/EBIT of 0.41. The 5-year average EV/EBIT is 0.07. The thresholds are as follows: Strongly Undervalued below -3.06, Undervalued between -3.06 and -1.50, Fairly Valued between 1.63 and -1.50, Overvalued between 1.63 and 3.20, and Strongly Overvalued above 3.20. The current Forward EV/EBIT of 0.41 falls within the Historic Trend Line -Fairly Valued range.

24.91

Vyne Therapeutics Inc. (VYNE) has a current PS of 24.91. The 5-year average PS is 57.36. The thresholds are as follows: Strongly Undervalued below -37.27, Undervalued between -37.27 and 10.05, Fairly Valued between 104.68 and 10.05, Overvalued between 104.68 and 152.00, and Strongly Overvalued above 152.00. The current Forward PS of 24.91 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Vyne Therapeutics Inc. (VYNE) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.35. The thresholds are as follows: Strongly Undervalued below -5.21, Undervalued between -5.21 and -3.28, Fairly Valued between 0.59 and -3.28, Overvalued between 0.59 and 2.52, and Strongly Overvalued above 2.52. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.37

P/FCF

Vyne Therapeutics Inc. (VYNE) has a current P/FCF of -0.37. The 5-year average P/FCF is -0.80. The thresholds are as follows: Strongly Undervalued below -3.72, Undervalued between -3.72 and -2.26, Fairly Valued between 0.66 and -2.26, Overvalued between 0.66 and 2.12, and Strongly Overvalued above 2.12. The current Forward P/FCF of -0.37 falls within the Historic Trend Line -Fairly Valued range.

Vyne Therapeutics Inc (VYNE) has a current Price-to-Book (P/B) ratio of 0.57. Compared to its 3-year average P/B ratio of 0.52 , the current P/B ratio is approximately 10.10% higher. Relative to its 5-year average P/B ratio of 1.09, the current P/B ratio is about -47.50% higher. Vyne Therapeutics Inc (VYNE) has a Forward Free Cash Flow (FCF) yield of approximately -199.33%. Compared to its 3-year average FCF yield of -177.56%, the current FCF yield is approximately 12.26% lower. Relative to its 5-year average FCF yield of -164.62% , the current FCF yield is about 21.08% lower.

0.57

P/B

Median3y

0.52

Median5y

1.09

-199.33

FCF Yield

Median3y

-177.56

Median5y

-164.62

Competitors Valuation Multiple

The average P/S ratio for VYNE's competitors is 4.54, providing a benchmark for relative valuation. Vyne Therapeutics Inc Corp (VYNE) exhibits a P/S ratio of 24.91, which is 448.49% above the industry average. Given its robust revenue growth of 39.67%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of VYNE decreased by 76.32% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 121.00K to 169.00K.

The secondary factor is the Margin Expansion, contributed -56.27%to the performance.

Overall, the performance of VYNE in the past 1 year is driven by Revenue Growth. Which is more sustainable.

39.67%

121.00K → 169.00K

Revenue Growth

-56.27%

-10.05K → -4.39K

Margin Expansion

-59.72%

-1.82 → -0.73

P/E Change

-76.32%

2.35 → 0.56

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Vyne Therapeutics Inc (VYNE) currently overvalued or undervalued?

What is Vyne Therapeutics Inc (VYNE) fair value?

VYNE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Vyne Therapeutics Inc (VYNE) is between 0.21 to 1.96 according to relative valuation methord.

How does VYNE's valuation metrics compare to the industry average?

What is the current P/B ratio for Vyne Therapeutics Inc (VYNE) as of Jan 08 2026?

As of Jan 08 2026, Vyne Therapeutics Inc (VYNE) has a P/B ratio of 0.57. This indicates that the market values VYNE at 0.57 times its book value.

What is the current FCF Yield for Vyne Therapeutics Inc (VYNE) as of Jan 08 2026?

As of Jan 08 2026, Vyne Therapeutics Inc (VYNE) has a FCF Yield of -199.33%. This means that for every dollar of Vyne Therapeutics Inc’s market capitalization, the company generates -199.33 cents in free cash flow.

What is the current Forward P/E ratio for Vyne Therapeutics Inc (VYNE) as of Jan 08 2026?

As of Jan 08 2026, Vyne Therapeutics Inc (VYNE) has a Forward P/E ratio of -0.75. This means the market is willing to pay $-0.75 for every dollar of Vyne Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Vyne Therapeutics Inc (VYNE) as of Jan 08 2026?

As of Jan 08 2026, Vyne Therapeutics Inc (VYNE) has a Forward P/S ratio of 24.91. This means the market is valuing VYNE at $24.91 for every dollar of expected revenue over the next 12 months.

VYNE Valuation